FV-100

FV-100 is an investigational antiviral drug developed by Bristol-Myers Squibb for the treatment of herpes zoster, also known as shingles. It is a prodrug of CF-1743, which is a potent inhibitor of varicella zoster virus (VZV).

Mechanism of Action

FV-100 is a prodrug that is metabolized into its active form, CF-1743, in the body. CF-1743 inhibits the replication of VZV by interfering with the virus's DNA polymerase, an enzyme that is essential for the virus to multiply.

Clinical Trials

Several clinical trials have been conducted to evaluate the efficacy and safety of FV-100 in patients with herpes zoster. In a Phase II clinical trial, FV-100 was found to be more effective than valacyclovir, a commonly used antiviral drug, in reducing the severity and duration of shingles-associated pain.

Potential Advantages

FV-100 has several potential advantages over existing antiviral drugs for the treatment of herpes zoster. It is more potent against VZV, has a longer half-life, and may be associated with fewer side effects.

Potential Disadvantages

As an investigational drug, FV-100 is not yet approved for use in patients. Its safety and efficacy are still being evaluated in clinical trials.

See Also

• Antiviral drug
• Herpes zoster
• Varicella zoster virus
• Bristol-Myers Squibb
• Clinical trial

FV-100 Resources
Most recent articles Ongoing trials	Wikipedia